Literature DB >> 3166399

Timing of chemotherapy and surgery in a murine osteosarcoma model.

R S Bell1, Y F Roth, M C Gebhardt, D F Bell, A E Rosenberg, H J Mankin, H D Suit.   

Abstract

The sequential use of chemotherapy and surgery in the treatment of osteosarcoma developed in an empirical fashion without the benefit of investigations in animal models. The MGH-OGS murine osteosarcoma is a transplantable tumor that resembles the human disease with respect to histology, local invasiveness, metastatic characteristics, tumor ploidy, and its response to chemotherapy. We have used this tumor model to investigate the efficacy of preoperative, perioperative, and postoperative chemotherapy on the development of pulmonary metastases in three different experimental protocols. In each experimental design, perioperative chemotherapy demonstrated a significant advantage in preventing systemic relapse.

Entities:  

Mesh:

Substances:

Year:  1988        PMID: 3166399

Source DB:  PubMed          Journal:  Cancer Res        ISSN: 0008-5472            Impact factor:   12.701


  9 in total

1.  An orthotopic model of murine osteosarcoma with clonally related variants differing in pulmonary metastatic potential.

Authors:  C Khanna; J Prehn; C Yeung; J Caylor; M Tsokos; L Helman
Journal:  Clin Exp Metastasis       Date:  2000       Impact factor: 5.150

2.  A nude mouse model of human osteosarcoma lung metastases for evaluating new therapeutic strategies.

Authors:  S F Jia; L L Worth; E S Kleinerman
Journal:  Clin Exp Metastasis       Date:  1999       Impact factor: 5.150

3.  Timing of Adjuvant Chemoradiation in pT1-3N1-2 or pT4aN1 Esophageal Squamous Cell Carcinoma After R0 Esophagectomy.

Authors:  Leilei Wu; Zhenshan Zhang; Shuo Li; Linping Ke; Jinming Yu; Xue Meng
Journal:  Cancer Manag Res       Date:  2020-10-27       Impact factor: 3.989

4.  Relationship between initiation time of adjuvant chemotherapy and survival in ovarian cancer patients: a dose-response meta-analysis of cohort studies.

Authors:  Yi Liu; Tiening Zhang; Qijun Wu; Yisheng Jiao; Tingting Gong; Xiaoxin Ma; Da Li
Journal:  Sci Rep       Date:  2017-08-25       Impact factor: 4.379

5.  Prognostic Influence of the Time Interval between Surgery and Chemotherapy in Epithelial Ovarian Cancer.

Authors:  Xiao-Dong Liu; Yi Liu; Ting-Ting Gong; Jing-Yi Guo; Ya-Nan Wang; Ling Wang; Qi-Jun Wu; Yi-Sheng Jiao
Journal:  J Cancer       Date:  2018-10-18       Impact factor: 4.207

6.  Impact of the Time Interval from Neoadjuvant Chemotherapy to Surgery in Primary Ovarian, Tubal, and Peritoneal Cancer Patients.

Authors:  Ming Chen; Zhanpeng Chen; Manman Xu; Duo Liu; Tianyu Liu; Mian He; Shuzhong Yao
Journal:  J Cancer       Date:  2018-10-18       Impact factor: 4.207

7.  From the completion of neoadjuvant chemotherapy to surgery for colorectal cancer liver metastasis: What is the optimal timing?

Authors:  Qichen Chen; Rui Mao; Jianjun Zhao; Xinyu Bi; Zhiyu Li; Zhen Huang; Yefan Zhang; Jianguo Zhou; Hong Zhao; Jianqiang Cai
Journal:  Cancer Med       Date:  2020-09-04       Impact factor: 4.452

Review 8.  Novel evolutionary dynamics of small populations in breast cancer adjuvant and neoadjuvant therapy.

Authors:  Yael Artzy-Randrup; Tamir Epstein; Joel S Brown; Ricardo L B Costa; Brian J Czerniecki; Robert A Gatenby
Journal:  NPJ Breast Cancer       Date:  2021-03-11

9.  Variability in chemotherapy delivery for elderly women with advanced stage ovarian cancer and its impact on survival.

Authors:  Jd Wright; T Doan; R McBride; Js Jacobson; Dl Hershman
Journal:  Br J Cancer       Date:  2008-03-18       Impact factor: 7.640

  9 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.